

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)



(10) International Publication Number
WO 2024/238955 A3

(51) International Patent Classification:

A61K 38/22 (2006.01) C07K 16/40 (2006.01)
A61P 43/00 (2006.01) C12N 15/62 (2006.01)
C07K 14/47 (2006.01) C12N 15/63 (2006.01)
C07K 14/64 (2006.01)

(21) International Application Number:

PCT/US2024/030016

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/503,101	18 May 2023 (18.05.2023)	US
63/585,849	27 September 2023 (27.09.2023)	US
63/586,868	29 September 2023 (29.09.2023)	US
63/611,732	18 December 2023 (18.12.2023)	US
63/617,398	03 January 2024 (03.01.2024)	US

(71) Applicant: **TECTONIC THERAPEUTIC, INC.**
[US/US]; 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 (US).

(72) Inventors: **DIENER, John**; c/o Tectonic Therapeutic, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 (US). **KNIHTILA, Ryan**; c/o Tectonic Therapeutic, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 (US). **ALVES, Washington**; c/o Tectonic Therapeutic, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 (US). **MUSLIN, Anthony J.**; c/o Tectonic Therapeutic, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 (US). **GRUSWITZ, Franz**; c/o Tectonic Therapeutic, Inc., 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472 (US).

(74) Agent: **LEE, David M.** et al.; c/o Dechert LLP, One International Place, 41st Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

26 December 2024 (26.12.2024)

(54) Title: RELAXIN-2 FUSION PROTEIN ANALOGS AND METHODS OF USING SAME

(57) Abstract: The present disclosure provides relaxin-2 fusion protein analogs with enhanced *in vivo* half-life and methods for making the same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

WO 2024/238955 A3